Pharma Pulse 8/2/24: Poor Data is a Population Health Risk, Meta’s Earnings Calm AI Jitters & more
The latest news for pharma industry insiders.
October 23, 2026
The latest news for pharma industry insiders.
Integrated Delivery Networks have impacted everything from drug launches to sales approaches.
Approval marks the first time an immuno-oncology regimen has demonstrated a survival benefit for all adults with primary advanced or
Regulatory action marks the first engineered cell therapy approved for a solid tumor cancer in the United States.
The app provides users with lifestyle tips and plans based on the lifestyles of people living in regions with the
IDeate-Lung02 will compare ifinatamab deruxtecan to a physician’s choice of chemotherapy in patients with relapsed small cell lung cancer.
In an interview with Pharm Exec Associate Editor Don Tracy, Carlos Doti, VP, head of medical affairs, US oncology business
Results of the Phase III Clarity AD study found that Leqembi reduced cognitive decline by -0.95 on the Clinical Dementia
With a growing number of legal battles over women’s health issues, such as abortion and infertility, stakeholders are concerned about
Erzofri is the first patented paliperidone palmitate long-acting injectable developed in China to receive FDA approval for treating schizophrenia and
Ouva’s AI-powered technology will be added to AvaSure’s digital platform.
Approval of Zunveyl offers a novel approach with a dual mechanism of action designed to improve tolerability and efficacy in
MGI Tech Co. issued a statement detailing the use of its technology in improving the rates of genomic sequencing in
A single dose of giroctocogene fitelparvovec significantly reduced the mean total annual bleeding rate in patients with moderately severe to
An unexpected consequence of the COVID 19 pandemic has been a loss in trust of vaccines. Over the past three
The latest news for pharma industry insiders.
The study is expected to evaluate the safety of Iomab-ACT in sickle cell disease patients who are undergoing allogeneic bone
FDA’s Oncologic Drugs Advisory Committee acknowledged that Imfinzi met its primary endpoint of event-free survival in the treatment of resectable
The supplemental New Drug Application for brexpiprazole in combination with sertraline is supported by data from three randomized clinical trials
Expanded indication of Brineura allows for treatment of neuronal ceroid lipofuscinosis type 2 disease in both symptomatic and presymptomatic children.
The partnership will allow both group to expand their operations and provide more solutions to underserved communities.
Moving forward, Sage Therapeutics and Biogen intend to cease further clinical development of SAGE-324 for essential tremor.
The latest news for pharma industry insiders.
The trial is expected to include 40 patients across the United States who haven’t responded adequately to standard hypovolemic septic
The latest news for pharma industry insiders.
Approval of Spravato would mark the first monotherapy to be available on the market for treatment-resistant depression in the United
The AI-powered feature will provide detailed nutritional information based on photos of food taken by users.
By embracing technology and integrating it seamlessly into your brand narrative, you can create a more engaging, personalized, and effective
Dx&Vx identified multiple potential drug candidates using AI-based technology.
The two companies will continue to collaborate on the use of machine learning in improving precision medicine development.
The latest news for pharma industry insiders.
JAMA study aims to determine whether financial barriers impact access to mental health services.
This is the latest approval for Phathom Pharmaceutical’s GI treatment.
Treatment with CT-996 led to a significant placebo-adjusted mean weight loss of 6.1% within four weeks in participants with obesity
The latest news for pharma industry insiders.
Clearance of the NeuroLF Brain PET system marks Positrigo’s first device of its kind to be approved in the United
Ripston discusses the Biospecimen Management Consortium and how its working to develop best practices for driving sample excellence.
The agreement enables SOTIO to license multiple fully human bispecific antibodies from Biocytogen’s RenLite platform.
The two companies will use Astrana’s technology offerings to improve access.
DSP-5336 targets the menin and mixed-lineage leukemia protein interaction, crucial in various biological processes, including cell growth and genomic stability.
The global president of endomechanical and energy for Johnson & Johnson MedTech discusses the need for multidisciplinary care when treating
The CEO of Revelation Pharma discusses how compounding pharmacies may help solve the ongoing issue with drug shortages.
The latest news for pharma industry insiders.
Avexitide has received Breakthrough Therapy Designation by the FDA for post-bariatric hypoglycemia, congenital hyperinsulinism, and more.
JAMA study aims to discover how weight loss differs between patients receiving tirzepatide compared with semaglutide among a clinical population
Advancements in periodontal disease could make way for expansions in the dental space and other medical fields.
The AscellaHealth CEO discusses how new technologies are increasing the options in patient care.
Dr Peter Wahl, MLA, MS, Global Head of Scientific Affairs at CorEvitas, part of Thermo Fisher Scientific, covers key considerations
Dr. Varshney discusses how AI is being used to sort data and discover new molecules and indications for existing drugs.
JAMA study evaluates changes to out-of-pocket costs and utilization of type 2 diabetes medications once patients reach the age of
Body Vision’s AI-powered LungVision image system earned a place in Vizient’s innovative technology program.
Approval of the Mynx Control Venous vascular closure device was based on results from the ReliaSeal trial, which demonstrated 100%
In an interview with Pharm Exec Associate Editor Don Tracy, Kathy Lee-Sepsick, Founder, CEO, Femasys, discusses results of the Femaseed
Results from the Phase III STREAM Stage 2 study show the efficacy and safety of an all-oral bedaquiline-containing regimen for
The latest news for pharma industry insiders.
The Fast Track designation for INZ-701 was based nonclinical pharmacology data and preliminary safety and efficacy data from the ongoing
Results of the Phase III CARTITUDE-4 study showed that treatment with Carvykti achieved a more significant improvement in overall survival
The platform is similar to other recent digital platforms in that it is designed to reduce drug costs.
The latest news for pharma industry insiders.
In an interview with Pharm Exec Associate Editor Don Tracy, Kathy Lee-Sepsick, Founder, CEO, Femasys, offers a description of how
The latest news for pharma industry insiders.
The latest news for pharma industry insiders.
MTX325 is in Phase I trials and is believed to be able to modify the course of the disease.
Funding from the Biomedical Advanced Research and Development Authority (BARDA) is expected to support the late-stage development and licensure of
The company announced that it has partnered with Adena Health and The Ohio State University Health Plan Solutions.
Kisunla is the first amyloid plaque-targeting therapy that allows for stopping treatment upon plaque removal, company says.
As previously announced, Michael assumed the role on July 1.
Reportedly, the liquid formulation of Tepylute eliminates the need for complex and time-consuming reconstitution, providing consistent dosing accuracy and allowing
The platform utilizes standards set forth in a recently published document from the CDC.
The latest news for pharma industry insiders.
In an interview with Pharm Exec Associate Editor Don Tracy, Leonard Mazur, Co-founder, CEO, Citius Pharmaceuticals, offers an update on
Ohtuvayre is the first inhaled product with a novel mechanism of action for chronic obstructive pulmonary disease to be approved
A Q&A with Russell Reynolds’ Global Lead of CEO & Executive Transition Practice, Ty Wiggins, PhD.
The inclusion of Vaxelis in the CDC’s preferential recommendations is expected to influence vaccine administration strategies and public health policies
UltraSight will join the AI marketplace.
The Complete Response Letter was issued as a result of inspection findings at a third-party manufacturing facility, unrelated to patritumab
Veeva’s vice president of global business consulting discusses recent trends in HCP access and how the pharma industry is reacting.
Results from three randomized clinical trials show safety and efficacy of a brexpiprazole-sertraline combination in adult patients with post-traumatic stress
The latest news for pharma industry insiders.
Investment is expected to fund a new fill and finish manufacturing facility to enhance production of injectable treatments for obesity
The insurance brokerage firm acquired company’s in Pennsylvania, North Carolina, Mississippi, and Iowa.
Approval of Wakix marks the first time a non-scheduled treatment option for excessive daytime sleepiness has been approved for patients
The online program is required for brokers and agents to sell Medicare Advantage Plans.
The company announced updates to its software to focus on this issue.
The latest news for pharma industry insiders.
The CTO of Authenticx discusses preventing bias from becoming part of AI models.
Expansion of Elevidys includes patients over the age of four years with Duchenne muscular dystrophy regardless of their ambulatory status.
Results of the PURPOSE 1 trial indicated that a twice-yearly injection of lenacapavir outperformed the once-daily oral Truvada preventing HIV
Data from an early phase trial published in Nature found that Parkinson disease patients treated with UB-312 experienced significant improvements
Q&A with Evaluate’s Paul Verdin digs deeper into the data-backed drivers likely to sway the future growth and jockeying of
Approval of Skyrizi marks the first IL-23 specific inhibitor approved for both ulcerative colitis and Crohn disease of similar severity,
Click the title above for a link to open the Pharmaceutical Executive June 2024 issue in an interactive PDF format.
Data presented at the European Hematology Association Congress indicated that patients with chronic lymphocytic leukemia treated with Imbrivica had a
According to the company, the additional software makes it algorithm more accurate.
How pharma and biotech leaders can navigate today’s challenging landscape—focusing on revamped approaches in business operations, talent strategy and development,
AstraZeneca’s Farxiga has previously been approved by the FDA as an adjunct to diet and exercise to improve glycemic control
Investigators followed a group of people born from 1990-1996 to assess whether the association between preterm birth and income differs
Hypermedica and Ro announced platforms to help patients find access to affordable weight loss medications.
What pharma needs to do to keep up with the rise in value-based care.
A Q&A with Egon Zehnder’s Sergio Della Zassa about what biopharma executives and search firms are looking for in terms
Arexvy receives expanded indication to include adults aged 59 years and younger to prevent RSV lower respiratory tract disease.
The partnership is described as the first of its kind.
Data published in the New England Journal of Medicine from Gilead’s Phase IIb MYR204 found the bulevirtide/ pegylated interferon alfa-2a
In this part of his Pharmaceutical Executive video interview, Brice Challamel, Vice President, AI Products & Platforms, Moderna, discusses their
The latest news for pharma industry insiders.
According to the manufacturer, the LFR-260 features advanced technology that allows patients to compare multiple prescriptions simultaneously, eliminating the need
Approval of Rytelo could provide patients with lower-risk myelodysplastic syndromes with extended periods without the need for red blood cell
The new agency will operate under the name Deerfield Group, and will also include Verge Scientific Communications.
Now more than two years into launching his alternative and transparent drug payment model, the longtime entrepreneur, in an interview
The latest news for pharma industry insiders.
A similar application was also submitted to the EMA for the expanded use of Prezcobix to treat children aged 6
The industry has struggled to recruit talent for years, and the challenge is only getting more difficult. Pharma companies need
Reportedly, data from the IMROZ study marks the first time an anti-CD38 monoclonal antibody combined with standard-of-care therapy has demonstrated
The latest news for pharma industry insiders.
Results of the ADRIATIC trial indicated that treatment with Imfinzi after standard-of-care concurrent chemoradiotherapy improves overall survival and progression-free survival
The platforms are described as being first-in-category for the pharma industry.
Alkermes’ chief information officer discusses how he helped develop and build a welcoming workplace.
The latest news for pharma industry insiders.
Under terms of the deal, Akili will become a wholly owned subsidiary of Virtual Therapeutics, with Akili shareholders receiving $0.4340
Understanding the Impact of the Veradigm Network on Value-Based Healthcare Delivery
Results of a Phase III trial indicated that Scemblix was more effective than standard-of-care tyrosine kinase inhibitors in treating newly
In an interview with Pharm Exec Associate Editor Don Tracy, Karen Rodriguez-Lorenc, Global Program Head of Linvosoltamab, Regeneron talks about
Approval of Onyda XR marks the first liquid non-stimulant medication for attention-deficit hyperactivity disorder to hit the market in the
The latest news for pharma industry insiders.
Priority review designation for Keytruda is based on promising results from the Phase II/III IND.227/KEYNOTE-483 trial, which demonstrated improved overall
In an interview with Pharm Exec Associate Editor Don Tracy, Karen Rodriguez-Lorenc, Global Program Head of Linvosoltamab, Regeneron talks key
The acquisition of a novel therapy for atopic dermatitis includes an all-cash transaction totaling approximately $1.25 billion.
The CEO of AION Labs discusses both the new ways that AI is being implemented in drug development and why
The company is collaborating with CPESN USA to bring more services to customers at independent pharmacies across the country.
The latest news for pharma industry insiders.
The latest news for pharma industry insiders.
Cencora’s associate director of value and access strategy for its commercialization strategy & access solutions division discusses the current state
Under terms of the agreement, Nona Biosciences is expected to receive an upfront payment of $19 million, with the potential
Cityblock is partnering with Sunshine Health in Florida.
Joint venture expected to utilize Degron’s GlueXplorer platform to identify, validate, and optimize molecular glue degraders.
The latest news for pharma industry insiders.
Approval for the Phase III protocol of LAE002 Plus LAE001 come as a result of posiive Phase II data, which
Inizio’s chief operations officer discusses how pharmaceutical companies are tailoring their product launch strategies to meet the diverse needs of
In an interview with Pharm Exec Associate Editor Don Tracy, Robert Zirkelback, Chief Public Affairs Officer, Head of Strategic Initiatives,
The latest news for pharma industry insiders.
In an interview with Pharm Exec Associate Editor Don Tracy, Tala Fakhouri, at Financial Times’ US Pharma and Biotech Summit,
Experts discuss how attempts to solve the drug pricing problem in the US are working.
alternatives to a Torch Disposable A Torch Disposable stands out in the vaping world for its comfortable form factor, good
In an interview with Pharm Exec Associate Editor Don Tracy, Robert Zirkelback, Chief Public Affairs Officer, Head of Strategic Initiatives,
Experts discuss how the upcoming election is impacting the pharma industry, and how either party’s victory could change the landscape
A Q&A with Professor Frances Frei of the Harvard Business School, who discusses how leaders create the conditions for organizations
Imdelltra (tarlatamab-dlle) is the first T-cell engager therapy approved for extensive stage small cell lung cancer.
Tala Fakhouri spoke at the conference about FDA’s approach to determining when it even needs to regulate the usage of
In an interview with Pharm Exec Associate Editor Don Tracy, Carmen Villar, VP, ESG & Corporate Citizenship, Gilead Scienes discusses
KOLs in the sector examine the current dealmaking landscape, including the status of available capital.
The latest news for pharma industry insiders.
In an interview with Pharm Exec Associate Editor Don Tracy at Financial Times’ US Pharma and Biotech Summit, Tala Fakhouri,
The platform will use AI technology to provide pharmacists with more tools.
Novo Holdings is expected to acquire 60% of Single Use Support, with the remaining shares being held by Danaher and
In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora discusses ways that cell
Click the title above for a link to open the Pharmaceutical Executive May 2024 issue in an interactive PDF format.
In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Melissa Lattanzi, VP, Emerging Therapies, Cencora discusses the process
Industry experts, in a roundtable discussion, explore the evolution of brand engagement in the age of AI, including the growing
Study findings indicated that psilocybin can reduce the symptoms of depression, with response and remission rates showing significant support.
Improving the US Supply Chain for Better Patient Outcomes
From Big Pharma to biotech—and a globe-spanning journey along the way—Yvonne Greenstreet, this year’s Healthcare Businesswomen’s Association Woman of the
In this Pharmaceutical Executive video interview, Panna Sharma, CEO, Lantern Pharma, discusses how LP-284 uniquely addresses unmet needs compared to
Now-unclear timing on rate cuts puts onus back on fundamentals.
A greater shift from paper records and physical assets is achievable.
The latest news for pharma industry insiders.
The collaboration is a part of a broader strategy to combat cardiometabolic and rare diseases.
The new care center will offer primary care services to uninsured and underinsured patients in the Wilmington, North Carolina, area.
In this Pharmaceutical Executive video interview, Panna Sharma, CEO, Lantern Pharma, explains which specific endpoints they’ll be looking at in
The latest news for pharma industry insiders.
Joint venture aims to develop up to 10 new cell and gene therapy products targeting areas with high unmet medical
The latest news for pharma industry insiders.
Myhibbin is reportedly the first FDA-approved liquid formulation of mycophenolate, a key immunosuppressant used to prevent organ rejection in transplant
Dr. Lewis used the AI-powered device on a patient with severe lumbar stenosis.
The two companies will work together to develop gene therapies in oncology.
Currently in Phase III of clinical trials, eneboparatide has shown promise in normalizing key calcium levels and improving bone health
Deal includes a number of radioligand therapies targeting solid tumors, such as breast, prostate, and lung cancers.
In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare
In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora, offers a synopsis on
Pharma Pulse 5/3/24: Wegovy Sales More Than Double, The Effects of the IRA & more
Partnership expected to utilize Walgreens’ pharmacies as recruitment and trial sites for a clinical study regarding obesity, weight issues, and
In this Pharmaceutical Executive video interview, Chris Martin, Chief Commercial Officer, Verona Pharma, discusses which skills or experiences he thinks
New formulation of Cyltezo aims to complement the existing low-concentration formulation and offer more treatment options for various chronic inflammatory
In this Pharmaceutical Executive video interview, Chris Martin, Chief Commercial Officer, Verona Pharma, discusses specific advantages for a small biotech
Treatment marks the first dissolving stent approved in the United States for treating chronic limb-threatening ischemia in arteries below the
The CEO of NewYorkBIO discusses why investors continue to flock to New York in the life sciences industry.
Approval of Libervant marks the first orally administered rescue medication for this age group to be cleared by the FDA
In this Pharmaceutical Executive video interview, Kalim Saliba, Chief Product Officer, Dotmatics discusses their Luma platform, Luma Lab Connect, and
Melton, customer advocacy executive at Magnolia, discusses how new technologies can be used to ensure data is accurate.
In this Pharmaceutical Executive video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One, discusses what other tactics healthcare marketers
Beqvez, a one-time gene therapy, offers hope to patients with moderate to severe hemophilia B who use regular factor IX
Approval update comes as a result of findings from Study 5310, which addressed Biktarvy’s pharmacokinetics, safety, and efficacy during pregnancy
In an interview with Pharm Exec Associate Editor Don Tracy, Howard Berman, Chairman, CEO, Coya Therapeutics offers a look at
The center will offer local residents with opportunities and training to enter the pharmacy work force.
Companies reported that the new formulation of Coartem met required pharmacokinetic profiles and displayed promising efficacy and safety treating malaria
The latest news for pharma industry insiders.
In an interview with Pharm Exec Associate Editor Don Tracy, Howard Berman, Chairman, CEO, Coya Therapeutics offers a preview on
The latest news for pharma industry insiders.
Lutathera is the first FDA-approved treatment for younger patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
LabConnect will utilize the consulting firm’s assets to improve its clinical trial services.
Industry executives dive into trends like utilizing AI and influencers for content creation, personalizing messages to the patient, combatting the